CYP1A1 and goblet cell carcinoma: It should be noted that GCC treatment constitutes an important risk factor related to the development of AFF, with nearly 50% of the patients presenting this associated comorbidity in several series.3, 24, 34 Of interest, CYP1A1 has recently been shown to suppress AMP‐activated protein kinase (AMPK) signaling,35 which has been related to the development of osteoporosis in experimental studies.